Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

p53 nuclear accumulation and ERα expression in ductal hyperplasia of breast in a cohort of 215 Chinese women

Authors: Xiao-yun Mao, Chui-feng Fan, Hua-chuan Zheng, Jing Wei, Fan Yao, Feng Jin

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Introduction

Women with ductal hyperplasia including usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH) have an increased risk of developing invasive ductal carcinoma (IDC) of breast. The importance of several molecular markers in breast cancer has been of considerable interest during recent years such as p53 and estrogen receptor alpha (ERα). However, p53 nuclear accumulation and ERα expression have not been assessed in ductal hyperplasia co-existing with ductal carcinoma in situ (DCIS) or IDC versus pure ductal hyperplasia without DCIS or IDC.

Materials and methods

We investigated p53 nuclear accumulation and ERα expression in breast ductal hyperplasia in a cohort of 215 Chinese women by immunohistochemistry (IHC), which included 129 cases of pure ductal hyperplasia, 86 cases of ductal hyperplasia co-existing with DCIS (41 cases) or IDC (45 cases).

Results

Nuclear p53 accumulation was identified in 22.8% of ADH (31/136), 41.5% of DCIS (17/41) and 42.2% of IDC (19/45), and no case of UDH (0/79). No difference in nuclear p53 accumulation was observed between pure ADH and ADH co-existing with DCIS (ADH/DCIS) or IDC (ADH/IDC) (P > 0.05). The positive rate of ERα expression was lower in ADH (118/136, 86.8%) than that in UDH (79/79, 100%) (P < 0.001), but higher than that in DCIS (28/41, 68.3%) or IDC (26/45, 57.8%) respectively (P < 0.001). The frequency of ERα expression was lower in ADH/DCIS (23/29, 79.31%) and ADH/IDC (23/30, 76.67%) than that in pure ADH (72/77, 93.51%) respectively (P < 0.05). There was a negative weak correlation between p53 nuclear accumulation and ERα expression as for ADH (coefficient correlation -0.51; P < 0.001).

Conclusions

Different pathological types of ductal hyperplasia of breast are accompanied by diversity in patterns of nuclear p53 accumulation and ERα expression. At least some pure ADH is molecularly distinct from ADH/CIS or ADH/IDC which indicated the two types of ADH are molecularly distinct entities although they have the same morphological appearance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boyle P, Levin B: World Cancer Report. International Agency for Research on Cancer. 2003 Boyle P, Levin B: World Cancer Report. International Agency for Research on Cancer. 2003
2.
go back to reference Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, Wang J, Li J, Du Q, Sun B: Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res. 2010, 29: 16-10.1186/1756-9966-29-16.CrossRef Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, Wang J, Li J, Du Q, Sun B: Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res. 2010, 29: 16-10.1186/1756-9966-29-16.CrossRef
3.
go back to reference Steinman S, Wang J, Bourne P, Yang Q, Tang P: Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007, 37: 127-134. Steinman S, Wang J, Bourne P, Yang Q, Tang P: Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007, 37: 127-134.
4.
go back to reference Liu T, Niu Y, Yu Y, Liu Y, Zhang F: Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol. 2009, 20: 441-448. 10.1093/annonc/mdn651.CrossRef Liu T, Niu Y, Yu Y, Liu Y, Zhang F: Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol. 2009, 20: 441-448. 10.1093/annonc/mdn651.CrossRef
5.
go back to reference Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005, 143: 446-457.CrossRef Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005, 143: 446-457.CrossRef
6.
go back to reference Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW: Benign breast disease and the risk of breast cancer. N Engl J Med. 2005, 353: 229-237. 10.1056/NEJMoa044383.CrossRef Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW: Benign breast disease and the risk of breast cancer. N Engl J Med. 2005, 353: 229-237. 10.1056/NEJMoa044383.CrossRef
7.
go back to reference Worsham MJ, Abrams J, Raju U, Kapke A, Lu M, Cheng J, Mott D, Wolman SR: Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. 2007, 13: 115-121. 10.1111/j.1524-4741.2007.00388.x.CrossRef Worsham MJ, Abrams J, Raju U, Kapke A, Lu M, Cheng J, Mott D, Wolman SR: Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. 2007, 13: 115-121. 10.1111/j.1524-4741.2007.00388.x.CrossRef
8.
go back to reference Poola I, Abraham J, Marshalleck JJ, Yue Q, Lokeshwar VB, Bonney G, Dewitty RL: Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clin Cancer Res. 2008, 14: 1274-1280. 10.1158/1078-0432.CCR-07-4053.CrossRef Poola I, Abraham J, Marshalleck JJ, Yue Q, Lokeshwar VB, Bonney G, Dewitty RL: Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clin Cancer Res. 2008, 14: 1274-1280. 10.1158/1078-0432.CCR-07-4053.CrossRef
9.
go back to reference Ranade KJ, Nerurkar AV, Phulpagar MD, Shirsat NV: Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients. Indian J Med Sci. 2009, 63: 481-490. 10.4103/0019-5359.58877.CrossRef Ranade KJ, Nerurkar AV, Phulpagar MD, Shirsat NV: Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients. Indian J Med Sci. 2009, 63: 481-490. 10.4103/0019-5359.58877.CrossRef
10.
go back to reference Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, Zhang Z: P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2010, 120: 509-517. 10.1007/s10549-009-0480-4.CrossRef Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, Zhang Z: P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2010, 120: 509-517. 10.1007/s10549-009-0480-4.CrossRef
11.
go back to reference Rossner P, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Kalra TS, Gaudet MM, Teitelbaum SL, Neugut AI, Santella RM: Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 2009, 13: 3847-3857. 10.1111/j.1582-4934.2008.00553.x.CrossRef Rossner P, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Kalra TS, Gaudet MM, Teitelbaum SL, Neugut AI, Santella RM: Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 2009, 13: 3847-3857. 10.1111/j.1582-4934.2008.00553.x.CrossRef
12.
go back to reference Sarid D, Ron IG, Shoshan L, Barnea I, Shina S, Baratz M, Greenberg J, Merimsky O, Ben-Yosef R, Lev-Ari S, Keidar Y, Yaal-Hahoshen N: Invasive breast cancer treated with taxol and epirubicin neo-adjuvant chemotherapy: the role in the outcome of the "crosstalk" between Erb receptors and p53. Anticancer Res. 2008, 28: 3147-3152. Sarid D, Ron IG, Shoshan L, Barnea I, Shina S, Baratz M, Greenberg J, Merimsky O, Ben-Yosef R, Lev-Ari S, Keidar Y, Yaal-Hahoshen N: Invasive breast cancer treated with taxol and epirubicin neo-adjuvant chemotherapy: the role in the outcome of the "crosstalk" between Erb receptors and p53. Anticancer Res. 2008, 28: 3147-3152.
13.
go back to reference Travis RC, Key TJ: Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003, 5: 239-247. 10.1186/bcr628.CrossRef Travis RC, Key TJ: Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003, 5: 239-247. 10.1186/bcr628.CrossRef
14.
go back to reference Willems P, De Ruyck K, Van den Broecke R, Makar A, Perletti G, Thierens H, Vral A: A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure. J Cancer Res Clin Oncol. 2009, 135: 1159-1168. 10.1007/s00432-009-0556-x.CrossRef Willems P, De Ruyck K, Van den Broecke R, Makar A, Perletti G, Thierens H, Vral A: A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure. J Cancer Res Clin Oncol. 2009, 135: 1159-1168. 10.1007/s00432-009-0556-x.CrossRef
15.
go back to reference Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH: Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 2008, 68: 1786-1796. 10.1158/0008-5472.CAN-07-5547.CrossRef Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH: Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 2008, 68: 1786-1796. 10.1158/0008-5472.CAN-07-5547.CrossRef
16.
go back to reference Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD: An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res. 2007, 9: R38-10.1186/bcr1734.CrossRef Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD: An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res. 2007, 9: R38-10.1186/bcr1734.CrossRef
17.
go back to reference Polyak K: Breast cancer: origins and evolution. J Clin Invest. 2007, 117: 3155-3163. 10.1172/JCI33295.CrossRef Polyak K: Breast cancer: origins and evolution. J Clin Invest. 2007, 117: 3155-3163. 10.1172/JCI33295.CrossRef
18.
go back to reference Matthews J, Gustafsson JA: Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2003, 3: 281-292. 10.1124/mi.3.5.281.CrossRef Matthews J, Gustafsson JA: Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2003, 3: 281-292. 10.1124/mi.3.5.281.CrossRef
19.
go back to reference Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9: R6-10.1186/bcr1639.CrossRef Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9: R6-10.1186/bcr1639.CrossRef
20.
go back to reference Goldhirsch A, Gelber RD, Coates AS: What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?. Nat Clin Pract Oncol. 2005, 2: 440-441. 10.1038/ncponc0296.CrossRef Goldhirsch A, Gelber RD, Coates AS: What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?. Nat Clin Pract Oncol. 2005, 2: 440-441. 10.1038/ncponc0296.CrossRef
21.
go back to reference Chen JQ, Russo J: ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009, 1796: 162-175. Chen JQ, Russo J: ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009, 1796: 162-175.
22.
go back to reference Tavassoli FA: Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification. Nat Clin Pract Oncol. 2005, 2: 116-117. 10.1038/ncponc0109.CrossRef Tavassoli FA: Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification. Nat Clin Pract Oncol. 2005, 2: 116-117. 10.1038/ncponc0109.CrossRef
23.
go back to reference Kok LF, Lee MY, Tyan YS, Wu TS, Cheng YW, Kung MF, Wang PH, Han CP: Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet. 2010, 281: 293-300. 10.1007/s00404-009-1094-0.CrossRef Kok LF, Lee MY, Tyan YS, Wu TS, Cheng YW, Kung MF, Wang PH, Han CP: Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet. 2010, 281: 293-300. 10.1007/s00404-009-1094-0.CrossRef
24.
go back to reference Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP: Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med. 2009, 7: 25-10.1186/1479-5876-7-25.CrossRef Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP: Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med. 2009, 7: 25-10.1186/1479-5876-7-25.CrossRef
25.
go back to reference Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE: Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997, 74: 346-358. 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9.CrossRef Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE: Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997, 74: 346-358. 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9.CrossRef
26.
go back to reference Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006, 6: 909-923. 10.1038/nrc2012.CrossRef Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006, 6: 909-923. 10.1038/nrc2012.CrossRef
27.
go back to reference Green DR, Chipuk JE: p53 and metabolism: Inside the TIGAR. Cell. 2006, 126: 30-32. 10.1016/j.cell.2006.06.032.CrossRef Green DR, Chipuk JE: p53 and metabolism: Inside the TIGAR. Cell. 2006, 126: 30-32. 10.1016/j.cell.2006.06.032.CrossRef
28.
go back to reference Bocangel D, Sengupta S, Mitra S, Bhakat KK: p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009, 29: 3741-3750. Bocangel D, Sengupta S, Mitra S, Bhakat KK: p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009, 29: 3741-3750.
29.
go back to reference Thompson AM, Lane DP: p53 transcriptional pathways in breast cancer: the good, the bad and the complex. J Pathol. 2010, 220: 401-403. Thompson AM, Lane DP: p53 transcriptional pathways in breast cancer: the good, the bad and the complex. J Pathol. 2010, 220: 401-403.
30.
go back to reference Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010, 17: 1398-1405. 10.1245/s10434-009-0889-3.CrossRef Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010, 17: 1398-1405. 10.1245/s10434-009-0889-3.CrossRef
31.
go back to reference Fan P, Wu Z, Cha X, Wang X, Wang S: Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer. Zhonghua Wai Ke Za Zhi. 1998, 36: 655-657. Fan P, Wu Z, Cha X, Wang X, Wang S: Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer. Zhonghua Wai Ke Za Zhi. 1998, 36: 655-657.
32.
go back to reference Rohan TE, Li SQ, Hartwick R, Kandel RA: p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1316-1323. 10.1158/1055-9965.EPI-06-0195.CrossRef Rohan TE, Li SQ, Hartwick R, Kandel RA: p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1316-1323. 10.1158/1055-9965.EPI-06-0195.CrossRef
33.
go back to reference Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM: Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res. 2001, 7: 2410-2414. Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM: Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res. 2001, 7: 2410-2414.
34.
go back to reference Pinzone JJ, Stevenson H, Strobl JS, Berg PE: Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol. 2004, 24: 4605-4612. 10.1128/MCB.24.11.4605-4612.2004.CrossRef Pinzone JJ, Stevenson H, Strobl JS, Berg PE: Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol. 2004, 24: 4605-4612. 10.1128/MCB.24.11.4605-4612.2004.CrossRef
35.
go back to reference McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, Dupont WD, Page DL: Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol. 2005, 29: 105-108. 10.1097/01.pas.0000146013.76881.d9.CrossRef McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, Dupont WD, Page DL: Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol. 2005, 29: 105-108. 10.1097/01.pas.0000146013.76881.d9.CrossRef
36.
go back to reference Spears M, Bartlett J: The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. Expert Opin Ther Targets. 2009, 13: 665-674. 10.1517/14728220902911509.CrossRef Spears M, Bartlett J: The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. Expert Opin Ther Targets. 2009, 13: 665-674. 10.1517/14728220902911509.CrossRef
37.
go back to reference Zagouri F, Sergentanis TN, Zografos GC: Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol. 2007, 5: 57-10.1186/1477-7819-5-57.CrossRef Zagouri F, Sergentanis TN, Zografos GC: Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol. 2007, 5: 57-10.1186/1477-7819-5-57.CrossRef
38.
go back to reference Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM: Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007, 67: 7746-7755. 10.1158/0008-5472.CAN-06-3724.CrossRef Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM: Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007, 67: 7746-7755. 10.1158/0008-5472.CAN-06-3724.CrossRef
39.
go back to reference Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, Fuchs-Young R: Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 2009, 69: 3405-3414. 10.1158/0008-5472.CAN-08-3628.CrossRef Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, Fuchs-Young R: Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 2009, 69: 3405-3414. 10.1158/0008-5472.CAN-08-3628.CrossRef
Metadata
Title
p53 nuclear accumulation and ERα expression in ductal hyperplasia of breast in a cohort of 215 Chinese women
Authors
Xiao-yun Mao
Chui-feng Fan
Hua-chuan Zheng
Jing Wei
Fan Yao
Feng Jin
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-112

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine